Apellis

Apellis is a Massachusetts-based biopharmaceutical company that develops and commercializes therapies for the treatment of debilitating diseases.

Business Model:

Revenue: $113M

Employees: 201-500

Detailed Apellis Information

Geographic Data

Apellis headquarters map

Address: 100 5th Avenue

City: Waltham

State: MA

Zip: 02451

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$0

Raised Total:

$169M

Metrics

1,418,585Website Global Rank

19,095Website Monthly Traffic

Twitter Followers

Description

Apellis is a Massachusetts-based biopharmaceutical company that develops and commercializes therapies for the treatment of debilitating diseases.

Contact Phone:
+16179775700

Contact Email:

Apellis went public on 11/9/2017 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
11/9/2017

IPO Valuation:
$689M

Ticker Symbol:
APLS

IPO Price:
$14/share

Amount Raised:
$150M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
2/2016 Series D 6 $47M Cormorant Asset Management
venBio Partners
Morningside Group
Hillhouse Capital Group
Epidarex Capital
Aju IB Investment
Cormorant Asset Management
1/2020 Post-IPO Equity 1 - Solasta Ventures
Solasta Ventures
6/2011 Series A $0 HealthCare Ventures
Keyhorse Capital (KSTC)
Masa Life Science Fund
Pegasus Capital
HealthCare Ventures
Keyhorse Capital (KSTC)
Masa Life Science Fund
Pegasus Capital
3/2022 Post-IPO Equity $402.5M Raymond James & Associates, Inc.
Oppenheimer & Co. Inc.
Robert W. Baird & Co.
12/2014 Series C $0 Aju IB Investment
Morningside Private Investors
Aju IB Investment
Morningside Private Investors
8/2017 Series E $0 venBio Partners
Epidarex Capital
Morningside Venture Investments
Clough Capital Partners
Sofinnova Investments
Sectoral Asset Management
F-Prime Capital
Vivo Capital
Cormorant Asset Management
Sectoral Asset Management
venBio Partners
Epidarex Capital
Morningside Venture Investments
Clough Capital Partners
Sofinnova Investments
Sectoral Asset Management
F-Prime Capital
Vivo Capital
Cormorant Asset Management
Sectoral Asset Management
8/2013 Venture Round 1 $6M Keyhorse Capital (KSTC)
7/2012 Series B 1 - Keyhorse Capital (KSTC)
Keyhorse Capital (KSTC)
5/2010 Venture Round 1 $1.7M Keyhorse Capital (KSTC)
4/2013 Funding Round 1 $20k XLerateHealth
XLerateHealth
7/2013 Venture Round $17.8M
7/2021 Post-IPO Debt $201.1M
1/2021 Debt $126.1M
11/2021 Post-IPO Equity $402.5M Oppenheimer & Co. Inc.
Robert W. Baird & Co.
Raymond James & Associates, Inc.
Oppenheimer & Co. Inc.
Robert W. Baird & Co.
Raymond James & Associates, Inc.
8/2017 Series E 9 $60M Sectoral Asset Management
Sofinnova
Vivo Capital
F-Prime Capital Partners
Morningside Ventures
venBio
Epidarex Capital
venBio Partners
Epidarex Capital
Morningside Venture Investments
Clough Capital Partners
Sofinnova Investments
Sectoral Asset Management
F-Prime Capital
Vivo Capital
Cormorant Asset Management
Sectoral Asset Management
1/2020 Post-IPO Equity 1 - Solasta Ventures
Solasta Ventures
12/2014 Series C 2 $33M Aju IB Investment
Morningside Private Investors
Aju IB Investment
Morningside Private Investors
7/2012 Series B 1 -
6/2011 Series A 4 $3M
Announced Date Name Price
11/2014 Potentia Pharmaceuticals

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research